Windtree Therapeutics (WINT) shares are trading higher by 32% at $2.63 in Friday’s premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target.
Windtree Therapeutics is a development biotechnology company focused on developing KL4 surfactant therapeutics for respiratory diseases. The company’s technology platform includes a peptide surfactant and novel drug delivery technology that provides a spray of KL4 surfactant without invasive methods. Premature neonatal syndrome.
The company is actively involved in the research and development of products focused on the treatment of surfactants for respiratory diseases and disorders, as well as the production and commercial distribution of well-known products.
With data readouts expected in both Phase 2 studies, WINT sees many possible value-creating catalysts as they look to the balance of the year. Furthermore, they are actively involved in WINT’s growth, and the degree of interest is encouraging. Importantly, their financial sheet now has the runway to assist fund these ongoing and future development operations, due to the successful execution of fundraising this quarter. They’re concentrating on execution and a year filled with significant accomplishments.